Leerink Partners recently hosted a Rare Disease Roundtable that included fireside chats with 24 biopharmaceutical companies. Following the event, analyst Joseph Schwartz released a report that included a list of 20 Outperform-rated names that attended the roundtable.
Here’s a list of some of the potential catalysts Schwartz sees for these companies.
Highlighted Stocks And Catalysts
Other Names
In addition to the specific names mentioned above, Leerink also sees potential upcoming catalysts for the following Outperform-rated names in the space:
- Auris Medical Holding AG EARS
- Epizyme Inc EPZM
- Fate Therapeutics Inc FATE
- Amicus Therapeutics, Inc. FOLD
- Insmed Incorporated INSM
- ProQR Therapeutics NV PRQR
- Uniqure NV> QURE
- Raptor Pharmaceutical Corp. RPTP
- Retrophin Inc RTRX
- SAGE Therapeutics Inc SAGE
- Acceleron Pharma Inc XLRN
- Zafgen Inc ZFGN
- Zogenix, Inc. ZGNX
Disclosure: The author holds no position in the stocks mentioned.
Image Credit: Public Domain© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
